Scilex (SCLX) Projected to Post Earnings on Tuesday

Key Points

• Scilex (NASDAQ:SCLX) is expected to announce its quarterly earnings on Tuesday, August 12th, with analysts predicting a loss of $4.55 per share and revenue of $26.25 million.
• The stock recently traded down 6.9% to $13.93 amid a total trading volume lower than its average, with a 52-week range from $3.60 to $50.40.
• Goldman Sachs recently increased its stake in Scilex by 31.2%, owning approximately 1.96% of the company, while institutional investors hold about 69.67% of the stock.

Scilex (NASDAQ:SCLX - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($4.55) per share and revenue of $26.25 million for the quarter.

Scilex Stock Performance

Shares of SCLX stock traded down $0.15 during trading on Friday, hitting $15.72. 97,782 shares of the company were exchanged, compared to its average volume of 264,786. The firm has a market capitalization of $109.25 million, a price-to-earnings ratio of -0.54 and a beta of 1.32. The business's 50-day simple moving average is $8.15 and its 200 day simple moving average is $8.62. Scilex has a twelve month low of $3.60 and a twelve month high of $49.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Scilex stock. Goldman Sachs Group Inc. increased its stake in Scilex Holding Company (NASDAQ:SCLX - Free Report) by 31.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 136,352 shares of the company's stock after purchasing an additional 32,449 shares during the period. Goldman Sachs Group Inc. owned approximately 1.96% of Scilex worth $34,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 69.67% of the company's stock.

Analysts Set New Price Targets

SCLX has been the topic of a number of research reports. D Boral Capital lowered shares of Scilex from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. D. Boral Capital reiterated a "hold" rating on shares of Scilex in a research report on Friday, April 11th.

Scilex Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.